Kangmei Pharmaceutical Co Ltd
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical … Read more
Market Cap & Net Worth: Kangmei Pharmaceutical Co Ltd (600518)
Kangmei Pharmaceutical Co Ltd (SHG:600518) has a market capitalization of $3.54 Billion (CN¥26.00 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #4318 globally and #426 in its home market, demonstrating a 1.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kangmei Pharmaceutical Co Ltd's stock price CN¥1.88 by its total outstanding shares 13828896690 (13.83 Billion).
Kangmei Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Kangmei Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $30.71 Billion to $3.54 Billion (-18.38% CAGR).
Index Memberships
Kangmei Pharmaceutical Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$1.18 Trillion | 0.22% | #90 of 285 |
Weight: Kangmei Pharmaceutical Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kangmei Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kangmei Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.85x
Kangmei Pharmaceutical Co Ltd's market cap is 0.85 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
514.40x
Kangmei Pharmaceutical Co Ltd's market cap is 514.40 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $30.71 Billion | $18.07 Billion | $2.76 Billion | 1.70x | 11.14x |
| 2016 | $32.76 Billion | $21.64 Billion | $3.34 Billion | 1.51x | 9.81x |
| 2017 | $41.43 Billion | $17.58 Billion | $2.15 Billion | 2.36x | 19.27x |
| 2018 | $17.24 Billion | $17.07 Billion | $374.49 Million | 1.01x | 46.04x |
| 2019 | $7.03 Billion | $11.45 Billion | -$4.66 Billion | 0.61x | N/A |
| 2020 | $5.05 Billion | $5.41 Billion | -$31.08 Billion | 0.93x | N/A |
| 2021 | $5.82 Billion | $4.15 Billion | $7.92 Billion | 1.40x | 0.74x |
| 2022 | $4.15 Billion | $4.18 Billion | -$2.69 Billion | 0.99x | N/A |
| 2023 | $3.51 Billion | $4.87 Billion | $102.52 Million | 0.72x | 34.19x |
| 2024 | $4.41 Billion | $5.19 Billion | $8.57 Million | 0.85x | 514.40x |
Competitor Companies of 600518 by Market Capitalization
Companies near Kangmei Pharmaceutical Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Kangmei Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Kangmei Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Kangmei Pharmaceutical Co Ltd's market cap moved from $30.71 Billion to $ 3.54 Billion, with a yearly change of -18.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.54 Billion | -1.57% |
| 2025 | CN¥3.60 Billion | -18.38% |
| 2024 | CN¥4.41 Billion | +25.81% |
| 2023 | CN¥3.51 Billion | -15.45% |
| 2022 | CN¥4.15 Billion | -28.80% |
| 2021 | CN¥5.82 Billion | +15.30% |
| 2020 | CN¥5.05 Billion | -28.15% |
| 2019 | CN¥7.03 Billion | -59.23% |
| 2018 | CN¥17.24 Billion | -58.38% |
| 2017 | CN¥41.43 Billion | +26.45% |
| 2016 | CN¥32.76 Billion | +6.70% |
| 2015 | CN¥30.71 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Kangmei Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.54 Billion USD |
| MoneyControl | $3.54 Billion USD |
| MarketWatch | $3.54 Billion USD |
| marketcap.company | $3.54 Billion USD |
| Reuters | $3.54 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.